Securities Code: 000952
Securities Abbreviation: Guangji Pharmaceutical
Announcement No.: 2026-053
Hubei Guangji Pharmaceutical Co., Ltd.
Resolution Announcement of the 19th (Extraordinary) Meeting of the 11th Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or significant omissions.
Key Information Prompt:
Hubei Guangji Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") plans to issue A-shares to specific targets (hereinafter referred to as the "Current Issuance" or "Current Issuance to Specific Targets"). The issuance target, Yangtze River Industry Investment Group Co., Ltd. (hereinafter referred to as "Yangtze River Industry Group"), is the controlling shareholder of the Company. Therefore, the subscription of shares in the Current Issuance by Yangtze River Industry Group and the signing of a conditional share subscription agreement with the Company constitute a related party transaction.
The matter of the current issuance of A-shares to specific targets was deliberated and approved at the 15th (Extraordinary) Meeting of the 11th Board of Directors held on February 11, 2026, and the 19th (Extraordinary) Meeting of the 11th Board of Directors held on July 20, 2026. It is subject to approval from the relevant state-owned asset regulatory authorities (if required), approval from the Company's shareholders' meeting, review and approval by the Shenzhen Stock Exchange, and registration approval from the China Securities Regulatory Commission before it can be implemented.
There is uncertainty regarding whether the issuance plan can obtain relevant approvals and consents, as well as the timing of obtaining such approvals and consents. Investors are reminded to pay attention to investment risks!
I. Convening of the Board Meeting
-
Time and method of meeting notice: The meeting notice was issued on July 14, 2026, via written delivery and email.
-
Time and method of meeting: The meeting was held on July 20, 2026, at the second-floor conference room of the administrative building, Dajin Industrial Park, Xichuan City, Hubei Guangji Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in a combination of on-site and teleconference format.
-
Attendance: 9 directors (including 3 independent directors) were entitled to attend the meeting, and all 9 directors were present. Messrs. Hu Ligang, Gong Cheng, Guo Shaozhi, and Fang Zhi voted in person, while Messrs. Liu Bo, Shi Shoutong, Liu Wei, Hong Kui, and Mei Jiandong voted via teleconference. The Company Secretary attended the board meeting.
-
The meeting was presided over by Chairman Hu Ligang.
-
The convening of this meeting complies with the "Company Law of the People's Republic of China" and the "Articles of Association" of the Company. The resolutions of the meeting are legal and valid.
II. Deliberation of the Board Meeting
(I) Deliberation and Approval of the "Proposal on Adjusting the Company's 2026 Plan for Issuing A-shares to Specific Targets"